SUTENT (Pfizer Laboratories Div Pfizer Inc)


Welcome to the PulseAid listing for the SUTENT drug offered from Pfizer Laboratories Div Pfizer Inc. This Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Pfizer Laboratories Div Pfizer Inc
NON-PROPRIETARY NAME: Sunitinib malate
SUBSTANCE NAME: SUNITINIB MALATE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA]
ROUTE: ORAL
DOSAGE FORM: CAPSULE
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2006-01-26
END MARKETING DATE: 0000-00-00


SUTENT HUMAN PRESCRIPTION DRUG Details:

Item DescriptionSUTENT from Pfizer Laboratories Div Pfizer Inc
LABELER NAME: Pfizer Laboratories Div Pfizer Inc
DEA SCHEDULE:
ACTIVE STRENGTH: 12.5(mg/1)
START MARKETING DATE: 2006-01-26
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0069-0550_fc8fc988-6d68-4f7b-b274-dd332905ad3d
PRODUCT NDC: 0069-0550
APPLICATION NUMBER: NDA021938

Other SUNITINIB MALATE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Pfizer Laboratories Div Pfizer IncSUTENT